Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Groups representing drug companies heavily increased their federal lobbying in President Trump's first year, according to a review of lobbying records. No health care lobbying group splurged more than the Pharmaceutical Research and Manufacturers of America, which spent $25.4 million in 2017 — a 30% jump from 2016.

The big picture: The pharmaceutical industry went on red alert after Trump said drug companies were "getting away with murder" and had "a lot of power." It's worked: In the year since, Trump and Congress have not changed drug pricing laws.

Expand chart
Data: U.S. Senate Lobbying Disclosure Act Database; Chart: Chris Canipe / Axios

The details: PhRMA spent the most in the first quarter, when Trump made his "getting away with murder" comments. The group lobbied on a plethora of issues, including fighting against measures that would allow importation of cheaper drugs and support of cutting drug subsidies to hospitals.

  • The Biotechnology Innovation Organization, another drug industry lobbying group, held its spending steady at $9.4 million in 2017.
  • The Association for Accessible Medicines, which represents generic drug makers, boosted its federal lobbying budget by 21% to $3.5 million.
  • The American Medical Association was the second-biggest spender on federal lobbying, raising its 2017 expenses by 11%, to $20.9 million.
  • The American Hospital Association spent $17.5 million last year, but that was actually a 7% decline.
  • The insurance industry also pulled back: Lobbying expenses dropped by 6% at America's Health Insurance Plans and 5% at the Blue Cross Blue Shield Association, even though Congress was pushing bills that would have cut Medicaid and individual health insurance subsidies.
  • Medical device lobbying group AdvaMed spent 14% more in Trump's first year and was rewarded with another two-year delay of the Affordable Care Act's medical device tax.

One big number: Overall, federal lobbying at just these 12 health care trade groups totaled $109 million in 2017 — or about $34 million more than what the Centers for Disease Control and Prevention spends on its opioid abuse and overdose prevention program. And that figure doesn't include the industry lobbying at the state level.

Go deeper

Broncos and 49ers the latest NFL teams impacted by coronavirus crisis

From left, Denver Broncos quarterbacks Drew Lock, Brett Rypien and Jeff Driskel during an August training session at UCHealth Training Center in Englewood, Colorado. Photo: Justin Edmonds/Getty Images

The COVID-19 pandemic has thrown the NFL season into chaos, with the Denver Broncos' quarterbacks sidelined, the San Francisco 49ers left without a home or practice ground and much of the Baltimore Ravens team unavailable, per AP.

Driving the news: The Broncos confirmed in a statement Saturday night that quarterbacks Drew Lock, Brett Rypien and Blake Bortles were identified as "high-risk COVID-19 close contacts" and will follow the NFL's mandatory five-day quarantine, making them ineligible for Sunday's game against New Orleans.

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: WHO: AstraZeneca vaccine must be evaluated on "more than a press release."
  2. Politics: McConnell temporarily halts in-person lunches for GOP caucus.
  3. Economy: Safety nets to disappear in DecemberAmazon hires 1,400 workers a day throughout pandemic.
  4. Education: U.S. public school enrollment drops as pandemic persists.
  5. Cities: Surge in cases forces San Francisco to impose curfew — Los Angeles County issues stay-at-home order, limits gatherings.
  6. Sports: NFL bans in-person team activities Monday, Tuesday due to COVID-19 surge — NBA announces new coronavirus protocols.
  7. World: London police arrest more than 150 during anti-lockdown protests — Thailand, Philippines sign deal with AstraZeneca for vaccine.

Tony Hsieh, longtime Zappos CEO, dies at 46

Tony Hsieh. Photo: FilmMagic/FilmMagic

Tony Hsieh, the longtime ex-chief executive of Zappos, died on Friday after being injured in a house fire, his lawyer told the Las Vegas Review-Journal. He was 46.

The big picture: Hsieh was known for his unique approach to management, and following the 2008 recession his ongoing investment and efforts to revitalize the downtown Las Vegas area.